scholarly article | Q13442814 |
P50 | author | Jonathan Betts | Q57560949 |
David Wareham | Q42749726 | ||
P2093 | author name string | Lynette M Phee | |
Binutha Bharathan | |||
P2860 | cites work | Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains | Q80758580 |
Combination therapy for carbapenem-resistant Gram-negative bacteria | Q87974612 | ||
Acinetobacter baumannii: an emerging opportunistic pathogen | Q26830893 | ||
Staphylococcus aureus elongation factor G--structure and analysis of a target for fusidic acid | Q27664084 | ||
Determination of minimum inhibitory concentrations | Q28203149 | ||
Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in Europe | Q28477449 | ||
Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America | Q29616084 | ||
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance | Q29617469 | ||
Fusidic acid pharmacology, pharmacokinetics and pharmacodynamics | Q33755492 | ||
Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus | Q34680589 | ||
A Review of Novel Combinations of Colistin and Lipopeptide or Glycopeptide Antibiotics for the Treatment of Multidrug-Resistant Acinetobacter baumannii. | Q34726120 | ||
Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii | Q35023321 | ||
When does 2 plus 2 equal 5? A review of antimicrobial synergy testing | Q35036156 | ||
The epidemiology and control of Acinetobacter baumannii in health care facilities | Q36382140 | ||
Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options | Q37150308 | ||
Growth retardation, reduced invasiveness, and impaired colistin-mediated cell death associated with colistin resistance development in Acinetobacter baumannii | Q37544704 | ||
Clinical experience of colistin-glycopeptide combination in critically ill patients infected with Gram-negative bacteria | Q37544860 | ||
The antimicrobial activity of fusidic acid | Q37906160 | ||
Genetic basis of antibiotic resistance in pathogenic Acinetobacter species | Q37944605 | ||
In vitro synergy of polymyxins with other antibiotics for Acinetobacter baumannii: a systematic review and meta-analysis | Q38281370 | ||
Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria | Q38287949 | ||
Antimicrobial heteroresistance: an emerging field in need of clarity. | Q38310639 | ||
Efforts to support the development of fusidic acid in the United States | Q38428027 | ||
Colistin and anti-Gram-positive bacterial agents against Acinetobacter baumannii | Q41736250 | ||
Genetic basis of resistance to fusidic acid in staphylococci. | Q41809069 | ||
Colistin heteroresistance in acinetobacter and its association with previous colistin therapy | Q41912289 | ||
In vitro interactions of anidulafungin with azole antifungals, amphotericin B and 5-fluorocytosine against Candida species | Q42171162 | ||
In vitro activity of the novel monosulfactam BAL30072 alone and in combination with meropenem versus a diverse collection of important Gram-negative pathogens | Q42255874 | ||
Control of multi-drug-resistant Acinetobacter baumannii outbreaks in an intensive care unit: feasibility and economic impact of rapid unit closure. | Q42288837 | ||
Combination testing of multidrug-resistant cystic fibrosis isolates of Pseudomonas aeruginosa: use of a new parameter, the susceptible breakpoint index | Q43253862 | ||
Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus | Q44852902 | ||
In vitro selection of resistance in Pseudomonas aeruginosa and Acinetobacter spp. by levofloxacin and ciprofloxacin alone and in combination with beta-lactams and amikacin | Q46557679 | ||
Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii | Q46939760 | ||
Effects of sodium fusidate in animal models of insulin-dependent diabetes mellitus and septic shock. | Q54607698 | ||
P433 | issue | 8 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | multiple drug resistance | Q643839 |
Acinetobacter baumannii | Q3241189 | ||
P1104 | number of pages | 7 | |
P304 | page(s) | 4544-4550 | |
P577 | publication date | 2015-05-18 | |
P1433 | published in | Antimicrobial Agents and Chemotherapy | Q578004 |
P1476 | title | Colistin and Fusidic Acid, a Novel Potent Synergistic Combination for Treatment of Multidrug-Resistant Acinetobacter baumannii Infections | |
P478 | volume | 59 |
Q28550341 | Activity of Colistin in Combination with Meropenem, Tigecycline, Fosfomycin, Fusidic Acid, Rifampin or Sulbactam against Extensively Drug-Resistant Acinetobacter baumannii in a Murine Thigh-Infection Model |
Q39629148 | Antibiotic combinations for controlling colistin-resistant Enterobacter cloacae. |
Q30235064 | Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options |
Q38940249 | Colistin: still a lifesaver for the 21st century? |
Q38686596 | Fusidic Acid: A Bacterial Elongation Factor Inhibitor for the Oral Treatment of Acute and Chronic Staphylococcal Infections |
Q36343547 | Host defense antimicrobial peptides as antibiotics: design and application strategies |
Q42407674 | In Vitro Activity of Fusidic Acid-Containing Combinations against Carbapenem-Resistant Acinetobacter baumannii Clinical Strains |
Q40162514 | In vitro and In vivo Activity of Theaflavin-Epicatechin Combinations versus Multidrug-Resistant Acinetobacter baumannii |
Q36363261 | Optimizing Polymyxin Combinations Against Resistant Gram-Negative Bacteria |
Q64266788 | Pharmacokinetic-pharmacodynamic modelling to investigate in vitro synergy between colistin and fusidic acid against MDR Acinetobacter baumannii |
Q92302901 | Rational Combinations of Polymyxins with Other Antibiotics |
Q58733403 | Sulbactam enhances the activity of sitafloxacin against extensively-drug resistant |
Q64891508 | The biological evaluation of fusidic acid and its hydrogenation derivative as antimicrobial and anti-inflammatory agents. |
Search more.